GH Research (GHRS) has released an update.
GH Research PLC has announced the elevation of Dr. Velichka ‘Villy’ Valcheva to the role of CEO, succeeding co-founder Dr. Theis Terwey. With over two decades of pharmaceutical and biotech industry leadership, Dr. Valcheva joined GH Research in 2023, contributing significantly to the company’s clinical development programs. The company, focused on innovative therapies for treatment-resistant depression, is progressing with its phase 2b trial and actively enrolling for a phase 1 study in the UK.
For further insights into GHRS stock, check out TipRanks’ Stock Analysis page.
